TY - JOUR T1 - The SARS-CoV2 envelope is distinct from host membranes, exposes pro-coagulant lipids, and can be inactivated <em>in vivo</em> by surfactant-containing oral rinses JF - medRxiv DO - 10.1101/2022.02.16.22270842 SP - 2022.02.16.22270842 AU - Zack Saud AU - Victoria J Tyrrell AU - Andreas Zaragkoulias AU - Majd B Protty AU - Evelina Statkute AU - Anzelika Rubina AU - Kirsten Bentley AU - Daniel A. White AU - Patricia Dos Santos Rodrigues AU - Robert C Murphy AU - Harald Köfeler AU - William J Griffiths AU - Jorge Alvarez-Jarreta AU - Richard William Brown AU - Robert G Newcombe AU - James Heyman AU - Manon Pritchard AU - Robert WJ Mcleod AU - Arvind Arya AU - Ceri-Ann Lynch AU - David Owens AU - P Vince Jenkins AU - Niklaas J. Buurma AU - Valerie B O’Donnell AU - David W. Thomas AU - Richard J. Stanton Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/17/2022.02.16.22270842.abstract N2 - The lipid envelope of SARS-CoV2 is an essential component of the virus, however its molecular composition is unknown. Addressing this knowledge gap could support the design of anti-viral agents, and further understanding of viral interaction with extracellular host proteins, infectivity, pathogenicity, and innate immune system clearance. Lipidomics analysis of SARS-CoV2 particles generated from Vero or A549 cells revealed that the virus envelope comprised mainly of phospholipids (PL), primarily phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylinositol (PI), with very little cholesterol, sphingolipids or other lipids, indicating significant differences from host membranes. Unlike healthy cellular membranes, procoagulant aminoPL (aPL), specifically PE and phosphatidylserine (PS), were present on the external side at levels far exceeding those seen on activated platelets. As a result, purified virions directly promoted coagulation. To investigate whether these differences enabled the viral envelope to be selectively targeted at relevant sites in vivo, we tested whether non-toxic oral rinses containing lipid disrupting chemicals could reduce viral infectivity. Products containing PL-disrupting surfactant solutions (cetylpyridinium chloride (CPC) or ethyl lauroyl arginate) met EN14476 virucidal standards in vitro, however products containing essential oils, PVP-I, or Chlorhexidine did not, nor did rinses containing components that altered the critical micelle concentration of CPC. This result was recapitulated in vivo, where a 30-second oral rinse with CPC-mouthwash eliminated live virus in the oral cavity of COVID19 patients for at least 1hr, while PVP-Iodine and saline mouthwashes were ineffective. Thus, the SARS-CoV2 lipid envelope is distinct from the host plasma membrane which may enable design of selective anti-viral approaches, it exposes PE and PS which may influence thrombosis, pathogenicity, and inflammation, and can be selectively targeted in vivo by specific oral rinses.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialhttps://www.isrctn.com/ISRCTN25647404Funding StatementRJS was partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC). VJT, DW, MP and PDSR are supported in part by the Welsh Government/EU Ser Cymru Programme. MBP was funded by a Wellcome Trust GW4CAT Training Fellowship (216278/Z/19/Z) and RM and MJP are Welsh Clinical Academic Training Fellows. VOD was a Royal Society Wolfson Merit Award Holder. AZ was funded by BBSRC (BB/W003376/1). Venture Life Group part-funded the clinical study, but had no input in study design, data analysis, or drafting of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Multicentre Research Ethics Committee approval was obtained (IRAS285247) and all procedures adhered to the Declaration of HelsinkiI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript ER -